Pharmacy practice is evolving rapidly under the influence of technological innovation, digital transformation, and advances in personalized medicine. Developments such as artificial intelligence–assisted drug discovery, digital therapeutics, pharmacogenomics, and novel clinical trial designs are reshaping how medicines are developed, regulated, and delivered. While these innovations hold considerable promise for improving patient outcomes, they also raise complex regulatory and ethical questions that demand careful attention. This review examines current challenges related to regulatory oversight of emerging technologies, disparities in global approval systems, and evolving clinical research models. It also explores ethical concerns surrounding data privacy, informed consent, algorithmic transparency, drug pricing, equitable access to therapy, and post-marketing safety monitoring. Particular emphasis is placed on the expanding responsibilities of pharmacists, who increasingly function as intermediaries between innovation, regulation, and patient care. As pharmaceutical science advances, regulatory systems must become more adaptive and ethically responsive. Strengthening policy frameworks while maintaining patient-centered values will be essential to ensure that innovation in modern pharmacy remains aligned with public health priorities and social responsibility.
Sulochana S. A.1*, Chaya M.2, Sowndharya N. C.3 (Thu,) studied this question.